Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

IDYA


Fundamental

Company: Ideaya Biosciences Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -3.79
Insider Own: 8.00%
Shs Outstand: 87.64M
Perf Week: -0.08%
Market Cap: 2.17B
Forward P/E: -
EPS next Y: -3.28
Insider Trans: 0.00%
Shs Float: 80.64M
Perf Month: 1.60%
Enterprise Value: 1.52B
PEG: -
EPS next Q: -0.82
Inst Own: 104.11%
Short Float: 12.51%
Perf Quarter: 10.41%
Income: -331.80M
P/S: 309.51
EPS this Y: -0.18%
Inst Trans: 3.18%
Short Ratio: 9.27
Perf Half Y: 29.22%
Sales: 7.00M
P/B: 2.26
EPS next Y Percentage: 2.53%
ROA: -32.93%
Short Interest: 10.09M
Perf YTD: -3.81%
Book/sh: 10.95
P/C: 3.23
EPS next 5Y: 5.84%
ROE: -35.09%
52W High: 37.80 -34.60%
Perf Year: -31.54%
Cash/sh: 7.64
P/FCF: -
EPS past 3/5Y: -33.53% -0.01%
ROIC: -33.65%
52W Low: 13.45 83.79%
Perf 3Y: 167.24%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: -36.96% -
Gross Margin: 42.56%
Volatility W: 3.24%
Volatility M: 4.86%
Perf 5Y: 96.97%
Dividend TTM: -
EV/Sales: 217.63
EPS Y/Y TTM: -73.55%
Oper. Margin: -5488.94%
ATR (14): 1.21
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 12.39
Sales Y/Y TTM: -41.48%
Profit Margin: -4740.03%
RSI (14): 50.87
Recom: 1.28
Dividend Gr. 3/5Y: - -
Current Ratio: 12.39
EPS Q/Q: -29.40%
SMA20: -0.73%
Beta: 0.12
Target Price: 46.88
Payout: -
Debt/Eq: 0.03
Sales Q/Q: -
SMA50: 2.94%
Rel Volume: 0.75
Prev Close: 24.53
Employees: 131
LT Debt/Eq: 0.03
Earnings: Aug 05 BMO
SMA200: 12.69%
Avg Volume: 1.09M
Price: 24.72
IPO: May 23, 2019
Option/Short: Yes / Yes
EPS/Sales Surpr.: -12.56% -100.00%
Trades:
Volume: 815,159
Change: 0.77%

Technical:


Latest News:

Amgen and Ideaya ax cancer combination trial - Fierce Biotech somewhat bearish
AMGN IDYA

Summary: Amgen and Ideaya Biosciences are winding down their cancer combination study involving PRMT5 inhibitor AMG 193 and MAT2A inhibitor IDE397. Ideaya will continue to explore MAT2A-PRMT5 combinations with its in-house PRMT5 inhibitor, IDE892, focusing on non-small cell lung cancer.

Full article
2025-02-13T13:45:02Z
Amgen and Ideaya ax cancer combination trial - Fierce Biotech somewhat bearish
AMGN IDYA

Summary: Amgen and Ideaya Biosciences are winding down their cancer combination study involving their PRMT5 inhibitors, leading to the termination of their collaboration. Meanwhile, Ideaya plans to focus on testing its PRMT5 inhibitor, IDE892, with MAT2A inhibitor IDE397 in non-small cell lung cancer patients.

Full article
2025-02-13T13:45:02Z
IDEAYA, Gilead To Evaluate Efficacy, Safety Of IDE397+Trodelvy Combination, Stock Up In ... somewhat bullish
IDYA GILD

Summary: IDEAYA Biosciences announced a clinical study collaboration and supply agreement with Gilead Sciences to evaluate IDE397 in combination with Trodelvy in NSCLC, updates expected in 2025, actively enrolling patients in various trials. Stock price is up by 3.78% in pre-market hours.

Full article
2025-02-13T12:00:29Z